Trials Sponsored by: Sanofi

You May Be Eligible for a Multiple Sclerosis Clinical Trial If:

You are between the ages of 18 and 55 years who has a current diagnosis of relapsing multiple sclerosis (RMS).

You are between the ages of 18 and 60 years who has a current diagnosis of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

You are between the ages of 18 and 55 years who has a current diagnosis of primary progressive multiple sclerosis (PPMS).

Tolebrutinib’s Phase II Study Results Summary:

In completed phase II study, 130 participants with relapsing remitting MS took one of 4 doses of tolebrutinib for 12 weeks either before or after taking placebo for 4 weeks. Compared to the placebo period, treatment with the highest dose of tolebrutinib (same as used in current clinical trials) resulted in 85% to 89% relative reduction in new MS brain lesions.

The most frequently reported side effects in the phase II clinical trial were headaches, and flu-like symptoms.

Learn more about the study drug >

Or click here to learn more about available clinical trials.

What are the different sub-types of multiple sclerosis?

RMS

RMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – usually persist for a short period of time (from a few days to a few months) and are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms disappear and there is no apparent progression of the disease during the periods of remission.
Approximately 85% of people with MS are initially diagnosed with RRMS.

nrSPMS

RMS can further evolve to non relapsing-SPMS, when symptoms are steadily getting worse (confirmed increase in disability is observed) and the attacks of new or increasing neurologic symptoms (also called relapses or exacerbations) are either missing or very rare.

PPMS

PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms and initial MS diagnostic, without early relapses or remissions. Occasional relapse may occur (exceptionally) with no remission and continuous increase in disability.

TAKE THE 30-SECOND QUESTIONNAIRE

Or click here to learn more about available clinical trials.

Wait… Can We Stay In Touch?

MyMStrials.com would like to stay in-touch.

No SPAM, we don’t sell or rent your information. Fully private.

No Thanks